Lite Strategy (LITS) Q4 2026 earnings summary

Executive summary

• Transitioned from oncology drug development to pre-clinical programs in nononcologic diseases and implemented a Litecoin (LTC) Treasury Strategy as a primary reserve asset, following a $100M PIPE financing in July 2025.

• Discontinued all clinical trials and reduced workforce in 2024, shifting focus to digital asset management and capital market operations, including a $25M share repurchase program.

• Sold ME-344 asset for $0.5M upfront and potential $62M in milestones; began pre-clinical work on voruciclib for nononcologic indications.

Financial highlights

• Net loss of $71.2M for FY ended June 30, 2026, compared to $15.9M net loss in FY 2025, driven by $54.4M unrealized losses on LTC holdings.

• Research and development expenses decreased 97% year-over-year to $0.1M due to cessation of clinical programs.

• General and administrative expenses fell 11% to $12.0M, reflecting lower personnel and legal costs, offset by higher noncash asset management and advisory fees.

• Cash and cash equivalents at $5.7M and unrestricted digital assets at $27.3M as of June 30, 2026.

• Raised $92.2M net from PIPE and ATM offerings; repurchased 4.4M shares for $4.9M.

Outlook and guidance

• Cash and digital assets expected to fund operations for at least 12 months; future capital needs may arise for further drug development or expansion of the LTC strategy.

• Exploring out-licensing or sale of drug candidates and potential expansion into LTC mining or other crypto-focused activities.